Residual risks of liver cancer persist after hepatitis C cure, finds study

National Taiwan University Hospital (NTUH), in collaboration with multiple medical centers across Taiwan, has found that patients with hepatitis C remain at a significantly elevated risk of hepatocellular carcinoma (HCC) even after successful viral eradication with direct-acting antivirals (DAAs), particularly if metabolic dysfunction-associated steatotic liver disease (MASLD) is present.